Hemostasis Abnormalities in Patients with Vascular Dementia and Alzheimer’s Disease

Summary

Since it has not been established to what extent abnormalities of hemostasis contribute to the occurrence and development of dementia, selected measurements of coagulation and fibrinolysis were obtained in elderly patients with Alzheimer’s disease (n = 22) or vascular dementia (n = 29), compared with healthy individuals in the same age range (n = 61). Hemostasis abnormalities were more frequent and marked in vascular dementia, being expressed as significant increases of plasminogen activator inhibitor type 1, von Willebrand factor, D-dimer. and activated factor VII. However, some hemostasis measurements (von Willebrand factor, activated factor VII) were abnormally high also in the patients with Alzheimer’s disease, a condition in which vascular damage is not considered to play a major pathogenetic role. It could not be established in this study whether or not these hemostatic abnormalities play a causal role in the pathogenesis of dementia, or whether they are secondary to inflammation and chronic vascular disease. Nevertheless, their presence may contribute to aggravating vascular disease.

• References

• 1 Hachinski V. Preventable senility: a call for action against the vascular dementia. Lancet 1992; 340: 645-648
• 2 Muñoz DG. The pathological basis of multi-infarct dementia. Alzheimer Dis Assoc Disord 1991; 5: 77-90
• 3 Walsh AC. Anticoagulant treatment of organic dementia. Alzheimer Dis Assoc Disord 1992; 6-1 letter
• 4 Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WRS, Haines AP, Stirling Y, Imeson JD, Thompson SG. Hemostatic function and ischemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 2: 533-537
• 5 Wilhemsen L, Svardsudd K, Korsan-Bengsten K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-505
• 6 Hamsten A, Wiman B, De Faire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557-1563
• 7 Hamsten A, Blombäck M, Wiman B, Svensson J, Szamosi A, De Faire U, Mettinger L. Haemostatic function in myocardial infarction. Brit Heart J 1986; 55: 58-66
• 8 Bauer KA, Mannucci PM, Gringeri A, Tradati F, Barzegar S, Kass BL, ten Cate H, Kestin AS, Brettler DB, Rosenberg RD. Factor IXa- factor Villa-cell surface complex does not contribute to the basal activation of the coagulation mechanism in vivo. Blood 1992; 79: 2039-2047
• 9 ten Cate H, Bauer KA, Levi M, Edgington TS, Sublett RD, Barzegar S, Kass BL, Rosenberg RD. The activation of factor X and prothrombin by recombinant factor Vila in vivo is mediated by tissue factor. J Clin Invest 1993; 92: 1207-1212
• 10 Jansson JH, Nilsson TK, Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J 1991; 66: 351-355
• 11 McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984; 34: 939-944
• 12 Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, Hofman A, Chui HC, Moody DM, O’Brien MD, Yamaguchi T, Grafman J, Drajer BP, Bennett DA, Fisher M, Ogata J, Kokmen E, Bermejo F, Wolf PA, Gorelick PB, Bick KL, Pajeau A, Bell MA, De Carli C, Culebras A, Korczyn AD, Bogoussla-vski J, Hartmann A, Scheinberg P. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Work Group. Neurology 1993; 43: 250-255
• 13 Hachinski GC, Iliff LD, Zilhka E, Du Boulay GH, McAllister VL, Marshall J, Ross Russell RW, Symon L. Cerebral blood flow in dementia. Arch Neurol 1975; 32: 632-637
• 14 Ligthart GJ, Corberand JX, Fournier C, Galanaud P, Hijmans W, Kennes B, Muller-Hermelink HK, Steinmann GC. Admission criteria for immunoge-rontological studies in man: the Senieur Protocol. Med Ageing Dev 1994; 28: 47-55
• 15 Coppola R, Tombesi S, Valentini F, Albertini A, Mannucci PM. Enzyme-linked immunosorbent assays of human factor VII based upon a monoclonal antibody that recognizes the native conformation of the protein. ThrombRes 1992; 68: 283-293
• 16 Wildgoose P, Nemerson Y, Hansen LL, Nielsen FE, Glazer S, Hedner U. Measurement of basal levels of factor Vila in hemophilia A and B patients. Blood 1992; 80: 25-28
• 17 Mannucci PM, Coppola R. von Willebrand factor. In: ECAT Assays Procedures. A Manual of Laboratory Techniques Jespersen J, Bertina RM, Haverkate F. eds Kluwer Academic Publisher; Lancaster, UK: 1992: 71-75
• 18 Cortellaro M, Boschetti C, Cofrancesco E, Zanussi C, Catalano M, de Gaetano G, Gabrielli L, Lombardi B, Specchia G, Tavazzi L, Tremoli E, della Volpe A, Polli E. and the PLAT Study Group. The PLAT Study: Hemostatic function to atherothrombotic ischemic events in vascular disease patients. Arterioscler Thromb 1992; 12: 1063-1070
• 19 Fowkes FGR, Lowe GOD, Housley E, Rattray A, Rumley A, Elton RA, McGregor IR, Dawes J. Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of CHD. Lancet 1993; 342: 84-86
• 20 Salomaa V, Stinson V, Kark JD, Folsom AR, Davis CE, Wu KK. Association of fibrinolytic parameters with early atherosclerosis. The ARIC Study. Circulation 1995; 91: 284-290